β-sheet containment by flanking prolines: Molecular Dynamic Simulations of the inhibition of β-sheet elongation by proline residues in human prion protein.

Mohd S. Shamsir* and Andrew R. Dalby**
*Biology Department, Faculty of Science, Universiti Teknologi Malaysia, 81310 Skudai, Johor.
**Department of Statistics, Peter Medawar Building, South Parks Road, School of Statistics, University of Oxford, Oxford OX1 3SY

ABSTRACT

Previous molecular dynamic simulations have reported elongation of the existing β-sheet in prion proteins. Detailed examination has shown that these elongations do not extend beyond the proline residues flanking these β-sheets. In addition, proline has also been suggested to possess a possible structural role in preserving protein interaction sites by preventing invasion of neighbouring secondary structures. In this paper, we have studied the possible structural role of the flanking proline residues by simulating mutant structures with alternate substitution of the proline residues with valine. Simulations showed a directional inhibition of elongation with the elongation progressing in the direction of valine including evident inhibition of elongation by existing proline residues. This suggests that the flanking proline residues in prion proteins may have a containment role and would confine the β-sheet within a specific length.

KEYWORDS

Molecular dynamics simulation, prion, proline, beta sheet
INTRODUCTION

Prions are a transmissible agent consisting of an abnormal isoform of the prion protein (PrP), designated PrPSC (1). PrPSC (SC for scrapie) is derived from a post-translational conformational transformation (2,3) of the cellular isoform, PrPC (C for cellular) (4,5). The term ‘Prion’ is a dyslexic acronym (6) coined by Prusiner for ‘Proteinaceous Infectious Particle’ to define a small proteinaceous infectious particle that resists inactivation by procedures which modify nucleic acids (7). According to the ‘protein only’ hypothesis, prion propagation involves a novel concept of transmission by proteinaceous material alone which is able to convert other normal isoforms to itself in an auto catalytic manner causing infection and disease proliferation without the transmission of a nucleic acid genome. Prion protein is unique in that it goes against two main dogmas in molecular biology. First, prion protein has shown that pathogens are able to replicate in the absence of nucleic acids. Secondly, prion protein defies the ‘one sequence, one conformation’ dogma because the conformation of the normal PrP sequence can transform into a different pathogenic conformation, either spontaneously or by association with pre-existing pathogenic material. (8). Prion diseases or transmissible spongiform encephalopathies (TSE) are characterised by spongiform degeneration and the accumulation of PrPSC in the brain. Prion diseases can also been grouped under the more general term of conformational diseases such as α1-antitrypsin deficiency, sickle cell anaemia and familial amyloid polyneuropathy as all these diseases have comparable inherent conformational instability of a specific protein that results in its deposition in the tissue of the affected organism. (9,10).

There are fifteen proline residues in the human prion protein structure with twelve residues in the flexible N terminus. The twelve proline residues in the N terminus are periodic and conformationally stabilised by copper (11). The other three proline residues are located within the globular domain of PrP. The anti-parallel β-sheet consisting of strand S2 is flanked at both ends by Pro158 and Pro165 with the opposing strand S1 flanked by a single proline at position 137 (Figure 1). Proline is an imino acid that has a pyrrolidine ring structure that prevents participation in the usual hydrogen bonding between NH and CO groups of other amino acids. The presence of the ring causes proline to be disfavoured in β-sheet structure as its φ angle is incompatible and it lacks one potential H-bond donor (12). Consequently, this makes its occurrence in β-sheet rare. In fact, the rare occurrences of proline in secondary structure have led to the practice of systematically substituting proline in mutagenesis studies, thus becoming a practical tool to identify segments involved in protein aggregation (13). Proline residues are more frequently found in sharp turns linking β-strands (β bends), kinks in transmembrane α-helices, at the edges of β-sheets or most frequently, within loops and disordered regions of proteins (13).

Previously, we have performed MD simulations at denaturing temperatures and residual structures showed evidence that suggested that the elongation of S1 and S2 in the prion protein is restricted and did not proceed beyond Pro158 and Pro165 flanking both sides of S2 and beyond proline137 on the C terminal end of S1 (14). Other MD simulations have also shown similar restrictions(15-18) even at elevated temperatures (19). The zipper-like progression of sheet formation could therefore be prevented by the presence of these proline ‘brackets’.

A study has also shown that proline is the residue most commonly found in the flanking segments of protein–protein interaction sites (20). Examination of over 1600
protein-protein interaction sites indicated that proline residues are commonly found within these flanking segments and the probability of occurrence in flanking segments is 2.5 times greater than elsewhere in the structure (20). As a result, proline ‘brackets’ have been proposed to perform a structural role in protecting the conformation and integrity of the interaction site by blocking the “invasion” of neighbouring secondary structures. (20). Investigation of the properties of proline delimited regions has also led to the discovery of the L-Type Ca$^{2+}$ channel binding site of calcineurin (21).

Presence of proline residues at the edge of β-sheet has also been proposed as a negative design feature to avoid aggregation and essentially serve as a capping mechanism (22). A survey of all the prion structures available in PDB revealed that proline ‘bracket’ is present and that the secondary structure architecture of the S2 strand is highly conserved in the different species, as expected from the high degree of sequence identity (Table 1).

This paper follows on from our earlier observations regarding the expansion of β-sheet (14) and examines if the existence of proline residues flanking β-strands S1 and S2 has a role in restraining the zippering process of the β-strands, therefore maintaining its length to a fixed number of residues. Variants with alternating proline substitutions have been used to examine if specific proline residue plays a distinct role in restraining the β-sheet.

MATERIALS AND METHODS

The starting structure for all the simulations was based on NMR structure of human prion protein domain in PDB designated 1QLX (23), which contains the C terminal globular structure of human prion consisting of residues 125-228. The structure 1QLX was used as wildtype and the variant structures were constructed using Deep View (24) by alternate substitution of proline with Val at position 135, 158 and 165 (Figure 1), creating seven mutant variants which were used for the simulations (Table 2).

The remainder of the structure is left unaltered. The disulphide bond between H2 and H3 was left intact as previous work showed that it remains oxidised in PrPSc and necessary for infectivity (25,26). All models were solvated in a box of explicit Simple Point Charge (SPC) water molecules and simulated using periodic boundary conditions (PBC) and particle mesh Ewald (PME) summation that have been shown to improved electrostatic interactions (27). Structures were minimised using 200 steps of the steepest descent method. Simulations were performed using GROMACS 3.1.4 package and the all-hydrogen function GROMOS96 (28). Simulations were carried out at 300 K and 500 K and isotropic pressure coupling was applied. All systems were equilibrated for 200 ps of solute position restrained molecular dynamics (MD). Unrestrained MD were performed on all variants for 2 ns with a LINCS algorithm 2 fs time step for each system. Simulations that showed a significant increase in β-sheet structure were repeated over a longer 10ns time-scale. Simulations were performed at pH 7. All the resulting trajectories were analysed using GROMACS utilities. The Cα root mean square deviations (RMSD) and Cα root mean square fluctuations (RMSF) relative to the average MD structure were calculated. The DSSP program was used to determine the percentage of secondary structure throughout the simulations(29). protein structure images were created using PyMOL (30) and protein Explorer (31).
RESULTS AND DISCUSSION

Structural deviations and fluctuations

Figure 2 shows the RMSD from the NMR structure as a function of simulation time for the C\textsubscript{\alpha} atom in each variant. Figure 3 shows the RMSF from the NMR structure a function of residue number for the C\textsubscript{\alpha} atom in each variant. The MD simulation showed that all variants were stable throughout the simulation. The C\textsubscript{\alpha} RMSD values for all eight variants increased during the first 0.1 ns before reaching a plateau at 0.15 ns – 0.3 ns (Figure 2). The RMSF of all variants showed that highest fluctuations occurred in the N terminus and the loop between helices (H2 and H3)(Figure 3) while the globular domain containing H2 and H3 remains relatively stable. Consequently, this created the groove pattern observed in reported MD simulations (14,17,19,32,33). The absence of rigid constraints imposed by proline residues on the N–C\textsubscript{\alpha} rotation in mutated structures did not substantially increase the fluctuations of the global conformation.

\beta-Sheet content

Figure 4 a-h shows number of residues forming \beta-sheets as a function of simulation time determined with DSSP. Only two variants VVV (Figure 4a) and PVV (Figure 4c) exhibited an increase in the number of residues participating in the \beta-sheet formation. MD simulation of VVV showed a discernible pair-like addition of two residues at a time at 0.5 ns and 1.6 ns (Figure 4a), suggesting a zipper process (34). A 2-residue extension occurred with the addition of four participating residues at the end of the simulation. MD simulation of PVV showed similar but faster pair-like increase during the first 0.2 ns. However, the extension in PVV exhibited higher fluctuations than VVV. The rest of the variants did not show a sustained increase in residue number and only showed fluctuations at around six residues (Figure 4b, d-h). The wildtype structure PPP showed the biggest fluctuations in \beta-sheet content the ranging between 0 to 7 residues (Figure 4g).

Structural evolutions: Elongation of existing \beta-sheets

Figure 5 a-d and Figure 6 a-d show the evolution of the secondary structures during the MD simulation as determined by DSSP. In all the simulations, the increase of \beta-sheets occurred through the extension of existing secondary structure and not by creation of new \beta-structures anywhere else in the protein structure.

Analysis of the secondary structure evolution revealed several interesting observations. The presence of the Pro158 and Pro165 flanking S2 seems to hinder the elongation of \beta-sheet S1 and S2 and its removal seems to induce \beta-sheet elongation. In VVV and PVV where these two proline residues have been replaced, the elongation occurred in both directions. In other variants, the expansion occurs away from an existing proline residue, thus creating a directional pattern (Figure 7). The presence of proline137 residue did not prevent sheet elongation. This is probably because proline137 is three residues further down the sequence and elongation may therefore occur on a longer timescale. Previous MD simulations have reported elongation of S1 and S2 (15,16,18,35-37) where all elongation of S2 was limited to within the six residues between proline158 and proline165.
Mechanism of elongation

The MD simulation trajectories for VVV, PVV and PPP were examined by superimposing sequential coordinate snapshots of structures to examine its conformational changes. The trajectory of VVV showed low fluctuations about the secondary structure and did not exhibit any major departure from the NMR structure. The reduced mobility of the residues Leu125-Gly126-Gly127-Tyr128 of the N terminus is evident by its movement into the globular structure as the zippering process realigns it to elongate the β-sheet. The fluctuations are constrained by the alignment process of the N terminus which results in the low RMSF range of 0.1-0.25 nm. In contrast, the Leu125-Gly127-Gly127-Tyr128 residues of PPP exhibited higher mobility due to the absence of the zippering and realignment process in VVV, as exemplified by the higher RMSF range of 0.1 – 0.5 nm. The trajectory of PVV exhibits intermediate behaviour with partial zippering and alignment. The Leu125-Gly126-Gly127-Tyr128 residues also showed reduced fluctuations compared to PPP. In contrast to the N terminus, residues forming segments between S1 and S2 that include H1 showed higher mobility in VVV compared to PPP and PVV. These increased fluctuations could be attributed to the absence of rigidity that Pro137 residues imposed on the N–Cα rotation, consequently limiting the plasticity of the same segment in PVV and PPP. The global stability of the structure and realignment of the N terminus suggest that the elongation of β-sheet occurs through the ability of valine to form hydrogen bonding after substituting proline, thus allowing the zippering process to continue.

Extended simulations

Extended MD simulations were performed to examine structural stability over a longer simulation period. Three variants; VVV, PVV, PPP and chicken prion 1U3M were simulated. VVV and PVV were selected as both showed an extended zippering of the β-sheet compared to the other variants while PPP is selected as a control representing the wildtype structure. 1U3M was chosen as the chicken prion structure(38) has a different proline trimer sequence at position 151-165-176 with approximately 30% sequence identity and is expected to show a different conformational behaviour.

Figure 8a-d shows the evolution of the secondary structures and Figure 9a-d shows the β-sheets content of each variant is shown in as determined by DSSP for (a) PVV, (b) PPP, (c) 1U5L and (d) VVV respectively. The result for PVV, PPP and VVV is similar to their initial runs where the increase of β-sheets occurred through the extension of existing secondary structure and not by creation of new β-structures anywhere else in the protein structure. The simulation is also stable without any changes in the overall protein conformation. The Cα RMSD values for all three variants stabilised after 0.3 ns and the Cα RMSF of all variants showed similar groove pattern signature observed in the 2ns MD simulation and to other reported MD simulations (14,17,19,32,33). The PVV variant showed a 100% increase in the number of residues participating in the β-sheet elongation to 13 residues similar to the initial 2ns MD simulation (Figure 9a). The longer simulation showed the β-sheet formation stabilising 4.4 ns and showed similar elongation mechanism to the earlier MD. The VVV variant also showed similar behaviour to the initial MD but with a higher degree of structural fluctuation in residues forming segments between S1 and S2 that include H1 compared to PVV. These larger fluctuations are exemplified by the failure to recruit adjacent residues to extend the β-sheet thus limiting the residue
participation to 8 amino acids (Figure 9d). In addition, the PPP variant also behaved in a similar manner to the initial MD simulation with the number of participating residues limited to between 6 and 9 (Figure 9b). The chicken prion also showed similar global conformational behaviour with the other 3 variants (Figure 8c). The secondary structures were maintained throughout the MD simulation but with larger fluctuations. The β-sheet content fluctuated throughout the simulation with the number of residues forming β-sheets fluctuating between 8 and 10 residues, similar to the ranges showed by VVV (Figure 9c). There was a temporary increase in the number of residues participating in β-sheet formation between 1 ns and 2 ns via the formation of a turn at the N terminal and creation an unstable triple stranded β-sheets (Figure 8c).

CONCLUSIONS
MD simulation of proline substituted structures showed that removal of proline residues induces directional elongation of β-sheet. The extended 10ns MD simulations have also shown that the β-sheet structure is stable for certain variant (PVV) but not VVV. This suggests that substituting all of the proline residues would reduce structural rigidity and increase fluctuations, therefore decreasing the propensity for adjacent strands to align and form β-sheets. It also showed that the wildtype variant (PPP) did not increase the β-sheet content at the end of the simulation. Simulation of the chicken prion did not show an increase even though there were the proline bracket were further apart than the human prion, suggesting other factors might contribute to the failure of the β-sheet to expand. This is not surprising as the low sequence identity with human prion protein might provide altered dynamics compared to mammalian derived prion proteins. Further work need to be done to study the molecular dynamics signature of chicken as well as other non-mammalian prion such as turtle and frogs (38).

The elongation occurred via a zippering process that is discernible by a pairing pattern caused by sequential recruitment of residues in pairs. Therefore, when the zipper-like process is halted by the flanking proline in the structure, this suggests that proline residues acts as a steric barrier by restricting the number of residues to six within the proline ‘bracket’ of proline158 and proline165. Interestingly, the six-residue length is near the intrinsic limit of conformational stability in anti-parallel β-sheet. Studies have shown that at least for some anti-parallel sequences, the conformational stability increases with strand length to a maximum of seven residues (39). The proline ‘bracket’ has also been shown to confine the secondary structures within it boundary even in elevated temperature. In contrast, the lone proline at residue 137 does not play a role in this ‘bracket’ but seems to contribute only to the structural rigidity of the segment between S1 and S2. If the presence of the proline ‘brackets’ is instrumental in determining and maintaining the length of the β-sheet to a fixed number of residues, there is a possibility that the length of additional β-sheet propagated by the residues 90-124 of the flexible N terminus (17) must not exceed a certain length of the seed strand (S2). Models of possible prion protofibrils created using electron crystallography data showed preservation of β-sheet length within the proline ‘bracket’, thus reinforcing its possible role in determining β-sheet length (40,41). Analysis of sequence evolutionary conservation in 27 mammalian and 9 avian PrP has shown that the proline ‘bracket’ segment PNQVYYYRP is highly conserved (42). In addition, the segment XPNXVY that contains proline158 has a
higher than average sequence conservation and appear to be needed for the stability of the "PrP-fold" (38). Experimentally, studies have shown that the existence of proline residues plays a significant role in protein conformational stability (43,44) and function (45). However, this unique role is attributed to the limited conformation that proline residues confer to the N–C\(_\alpha\) rotation and not because of its inability to form \(\beta\)-sheet hydrogen bonding. In addition, this is the first time MD simulations have shown the role of proline in maintaining the secondary structure in such a manner. Nevertheless, further work needs to be done by conducting a survey of existing protein structures to examine if this phenomena applies to other similarly structured proteins.
REFERENCES


### Table 1: Amino acid sequence alignment of the fragment 158–173 for the different species. The table shows NMR determined structures deposited in the PDB. It uses human sequence numbering with flanking proline residues underlined and β-sheet assigned structure consisting of amino acid residues VYY is highlighted in a continuous grey box.

<table>
<thead>
<tr>
<th>PDB ID</th>
<th>Species</th>
<th>157</th>
<th>158</th>
<th>159</th>
<th>160</th>
<th>161</th>
<th>162</th>
<th>163</th>
<th>164</th>
<th>165</th>
<th>166</th>
<th>167</th>
<th>168</th>
<th>169</th>
<th>170</th>
<th>171</th>
</tr>
</thead>
<tbody>
<tr>
<td>1QLX</td>
<td>Human</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>M</td>
<td>D</td>
<td>E</td>
<td>Y</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>1AG2</td>
<td>Mouse</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>Q</td>
<td>Y</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>1B10</td>
<td>Hamster</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>Q</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>1DWY</td>
<td>Bovine</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>Q</td>
<td>Y</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>1UW3</td>
<td>Sheep</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>R</td>
<td>Y</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>1XYJ</td>
<td>Cat</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>Q</td>
<td>Y</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>1XYQ</td>
<td>Pig</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>Q</td>
<td>Y</td>
<td>S</td>
<td>N</td>
</tr>
<tr>
<td>1XYW</td>
<td>Elk</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>Q</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>1XYK</td>
<td>Dog</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>Q</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>V</td>
<td>D</td>
<td>Q</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>1XU0</td>
<td>Frog</td>
<td>M</td>
<td>P</td>
<td>N</td>
<td>R</td>
<td>V</td>
<td>-</td>
<td>Y</td>
<td>R</td>
<td>P</td>
<td>M</td>
<td>Y</td>
<td>R</td>
<td>G</td>
<td>E</td>
<td>E</td>
</tr>
<tr>
<td>1U3M</td>
<td>Chicken</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>R</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>R</td>
<td>D</td>
<td>Y</td>
<td>S</td>
<td>S</td>
<td>-</td>
<td>-</td>
<td>P</td>
</tr>
<tr>
<td>1U5L</td>
<td>Turtle</td>
<td>Y</td>
<td>P</td>
<td>N</td>
<td>R</td>
<td>V</td>
<td>Y</td>
<td>Y</td>
<td>K</td>
<td>E</td>
<td>Y</td>
<td>N</td>
<td>D</td>
<td>R</td>
<td>-</td>
<td>S</td>
</tr>
<tr>
<td>Variant</td>
<td>IQLX</td>
<td>PPV</td>
<td>PVV</td>
<td>PVP</td>
<td>VPP</td>
<td>VVP</td>
<td>VPV</td>
<td>VVV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Res 135</td>
<td>P</td>
<td>P</td>
<td>P</td>
<td>P</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td>V</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Res 158</td>
<td>P</td>
<td>P</td>
<td>V</td>
<td>V</td>
<td>P</td>
<td>V</td>
<td>P</td>
<td>V</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Res 165</td>
<td>P</td>
<td>V</td>
<td>V</td>
<td>P</td>
<td>P</td>
<td>P</td>
<td>V</td>
<td>V</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2**: Variants of proline/Val construct used in the MD simulations
**FIGURE LEGENDS**

**Figure 1**: Ribbon diagram of S1, S2 and H1 with proline indicated by its ring. The diagram shows only S1, S2 and H1 with H2 and H3 omitted for clarity. The secondary structures are presented with helices and sheets.

**Figure 2**: RMS deviations of all proline variants as a function of time for all proline variants.

**Figure 3**: RMS fluctuations of all proline variants with residues numbered according to human prion residue sequence; blue bars denote α-helices, red bars β-sheets in wildtype structure; S1, sheet 1; S2, sheet 2; H1, helix 1; H2, helix 2; H3, helix 3 and black arrows indicate position of proline residues in the protein sequence.

**Figure 4**: The number of residues forming β-sheets as a function of simulation time determined with DSSP during the simulation (a) VVV (b) VPV (c) PVV (d) PPV (e) PVP (f) VVP (g) PPP (h) VPP

**Figure 5**: Secondary structure of variants as a function of simulation time determined by DSSP. The diagram shows (a) VVV (b) VVP(c) VPV (d) PVV variants. H1, H2 and H3 denote Helices 1, 2 and 3. S1 and S2 denote Sheet 1 and Sheet 2. The colour guide denotes types of secondary structure.

**Figure 6**: Secondary structure of variants as a function of simulation time determined with DSSP The diagram shows (a) VPP (b) PVP (c) PPV (d) PPP variants. H1, H2 and H3 denote Helices 1, 2 and 3. S1 and S2 denote Sheet 1 and Sheet 2. The colour guide denotes types of secondary structure.

**Figure 7**: Schematic diagram of the direction of the β-sheet expansion. The diagram shows the schematic of β-sheet expansion of all proline variants. The anti-parallel β-sheets are denoted by a pair of black boxes, the direction of the polypeptide denoted by black arrow, the presence and direction of expansion in grey arrows.

**Figure 8**: Secondary structure as a function of simulation time determined with DSSP during the simulation (a) PVV (b) PPP (c) 1U3M (d) VVV; S1, sheet 1; S2, sheet 2; H1, helix 1; H2, helix 2; H3, helix 3. The color guide designates types of secondary structure.

**Figure 9**: The number of residues forming β-sheets as a function of simulation time determined with DSSP during the simulation (a) PVV (b) PPP (c) 1U3M (d) VVV
Figure One
Figure Two
Figure 3
Figure 4 a-d
Figure 5 c-d
Figure 6 a-b
Figure 6 c-d
Figure 7
Figure 8 a-b
Figure 9b